PMC:7426526 / 77033-77507
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7426526","sourcedb":"PMC","sourceid":"7426526","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7426526","text":"The high costs are one point of contention regarding the biopsies and their analysis as well as the implementation of immunotherapies into the first and secondary line targeted therapies. However, considering the costs for therapies, comprising resection, and medication strategies, as well as the patient's sufferings due to a re-emerged full-blown cancer, the targeted therapy will help to save the patients and clinics from high personnel, emotional, and medicinal costs.","tracks":[]}